{"id":68171,"date":"2026-06-15T20:10:43","date_gmt":"2026-06-15T12:10:43","guid":{"rendered":"https:\/\/flcube.com\/?p=68171"},"modified":"2026-06-15T20:12:14","modified_gmt":"2026-06-15T12:12:14","slug":"merck-secures-nmpa-approval-for-enflonsia-clesrovimab-first-single-dose-rsv-monoclonal-antibody-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68171","title":{"rendered":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck &amp; Co., Inc. (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>marketing approval<\/strong> for <strong>Enflonsia (clesrovimab)<\/strong>, a <strong>long-acting monoclonal antibody (mAb)<\/strong> indicated for the <strong>prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV)<\/strong> in newborns and infants entering or born during their first RSV season.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Enflonsia (clesrovimab)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of RSV lower respiratory tract disease in infants<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>June 15, 2026<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>Single fixed dose, no weight measurement required<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Long-acting monoclonal antibody (mAb)<\/li>\n\n\n\n<li><strong>Target:<\/strong> RSV fusion glycoprotein<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First and only long-acting RSV mAb in China requiring no body weight measurement<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Induces passive immunity by binding to the RSV fusion glycoprotein, providing direct, rapid, and durable protection<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Single fixed dose for all infants regardless of body weight<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-timeline\" class=\"wp-block-heading\">Regulatory Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Milestone<\/th><\/tr><\/thead><tbody><tr><td>June 2024<\/td><td>First approved in the US as the first and only single-dose RSV mAb for infants of all body weights<\/td><\/tr><tr><td>April 2025<\/td><td>Submitted for approval in China with priority review designation<\/td><\/tr><tr><td>May 2025<\/td><td>MSD withdrew the application<\/td><\/tr><tr><td>June 6, 2026<\/td><td>Resubmitted application<\/td><\/tr><tr><td>June 15, 2026<\/td><td>Received NMPA approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Prior to this approval, <strong>nirsevimab<\/strong> from <strong>AstraZeneca\/Sanofi<\/strong> was the only similar product approved in China for RSV prevention. Enflonsia now becomes the first long-acting RSV monoclonal antibody in the Chinese market that eliminates the need for weight-based dosing calculations, potentially simplifying administration across diverse healthcare settings.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China RSV Burden:<\/strong> RSV represents a significant health burden for infants across China, with seasonal outbreaks causing substantial hospitalizations<\/li>\n\n\n\n<li><strong>Implementation Advantage:<\/strong> The single-dose, weight-independent administration could streamline implementation in both urban and rural healthcare settings<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> As the first and currently only long-acting RSV mAb with simplified dosing in China, Enflonsia is positioned to capture significant market share in the infant RSV prevention segment<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals and commercial expectations for Enflonsia. Actual results may differ due to risks including market adoption, competitive dynamics, and healthcare policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2675,176,903],"class_list":["post-68171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68171\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68171\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T12:10:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T12:12:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China\",\"datePublished\":\"2026-06-15T12:10:43+00:00\",\"dateModified\":\"2026-06-15T12:12:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1501.webp\",\"keywords\":[\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68171#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68171\",\"name\":\"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1501.webp\",\"datePublished\":\"2026-06-15T12:10:43+00:00\",\"dateModified\":\"2026-06-15T12:12:14+00:00\",\"description\":\"Merck & Co., Inc. (MSD, NYSE: MRK) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68171\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68171#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68171","og_locale":"en_US","og_type":"article","og_title":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China","og_description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.","og_url":"https:\/\/flcube.com\/?p=68171","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T12:10:43+00:00","article_modified_time":"2026-06-15T12:12:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68171#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68171"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China","datePublished":"2026-06-15T12:10:43+00:00","dateModified":"2026-06-15T12:12:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68171"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp","keywords":["Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68171#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68171","url":"https:\/\/flcube.com\/?p=68171","name":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68171#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp","datePublished":"2026-06-15T12:10:43+00:00","dateModified":"2026-06-15T12:12:14+00:00","description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68171#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68171"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68171#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp","width":1080,"height":608,"caption":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68171#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck Secures NMPA Approval for Enflonsia (Clesrovimab) \u2013 First Single-Dose RSV Monoclonal Antibody in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68171"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68171\/revisions"}],"predecessor-version":[{"id":68174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68171\/revisions\/68174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}